TAP1 and cancer: One notable aspect of our results is the prominent difference in the frequency of TAP1 and TAP2 cancer cell downregulation in NSCLC, as well as their dissimilar impact on surface antigenic peptide abundance and role in protection of cancer cells from T-cell attack.